{"id":58987,"date":"2018-03-02T17:05:34","date_gmt":"2018-03-02T15:05:34","guid":{"rendered":"http:\/\/www.reunion68.se\/?p=58987"},"modified":"2018-02-21T08:59:16","modified_gmt":"2018-02-21T06:59:16","slug":"26-05-21","status":"publish","type":"post","link":"https:\/\/www.reunion68.se\/?p=58987","title":{"rendered":"Possible hemophilia cure under study in Israeli hospital"},"content":{"rendered":"
\"Israel21c\"<\/a>Possible hemophilia cure under study in Israeli hospital<\/a><\/strong><\/span><\/h5>\n

Brian Blum <\/strong><\/span><\/p>\n

\n

US biotech company BioMarin enlists aid of Sheba Medical Center to take part in international trials of a \u2018magic bullet\u2019 treatment for hemophilia A.
\n<\/strong>
\nImage by Jarun Ontakrai\/Shutterstock.com<\/em><\/span><\/p>\n

Is a cure for hemophilia on the horizon? American biotechnology company BioMarin aims to find out with the help of Sheba Medical Center in Ramat Gan, Israel.<\/span><\/p>\n

BioMarin has chosen Sheba to take part in the next phase of international trials for what\u2019s being touted as a \u201cmagic bullet\u201d cure for hemophilia A, a genetic blood-clotting deficiency that results in patients bleeding longer after an injury and more easily bruising. Hemophilia A, which affects mostly men, can be life-threatening.<\/span><\/p>\n

BioMarin has developed a treatment using viruses to implant new genes into a patient\u2019s cells; a single dose seems to be enough to stop or even cure the disease.<\/span><\/p>\n

BioMarin has conducted an initial trial on nine patients \u2013 all stopped using clotting factor drugs to treat their hemophilia and their annualized bleeding rate fell from some 16 episodes a year to just one.<\/span><\/p>\n

Prof. Gili Kenet will run the project in Israel. Kenet, the director of the National Hemophilia Center and Institute of Thrombosis and Hemostasis at Sheba Medical Center, is impressed by what she\u2019s seen so far.<\/span><\/p>\n

\u201cPeople in the medical community are beginning to speak about curing hemophilia after a one-time treatment with this new drug,\u201d she said.<\/span><\/p>\n

Sheba\u2019s National Hemophilia Center treats more than 700 hemophiliacs a year and has about 50 patients currently participating in clinical studies. Kenet, an internationally known expert on hemophilia, thrombosis and hemostasis, is the current co-chair of the scientific subcommittee dealing with hemophilia A for the International Society of Thrombosis and Hemostasis.<\/span><\/p>\n

\u201cThese are exciting times, as there are options to cure hemophiliac patients,\u201d Kenet said. \u201cWe are hoping that results of this trial at Sheba will be good enough that this will be the therapy of choice that will able to stop this dreaded disease once and for all.\u201d<\/span><\/p>\n

Pending approval by the Israeli Ministry of Health, Sheba expects to begin enrolling patients shortly.<\/span><\/p>\n

\n
\n
\n
Zawarto\u015b\u0107 publikowanych artyku\u0142\u00f3w i materia\u0142\u00f3w nie reprezentuje pogl\u0105d\u00f3w ani opinii Reunion’68,
\nani te\u017c webmastera Blogu Reunion’68, chyba ze jest to wyra\u017anie<\/span><\/span> zaznaczone.
\nTwoje uwagi, linki, <\/span><\/span>w\u0142asne<\/span><\/span> artyku\u0142y<\/span><\/span> lub <\/span><\/span>wiadomo\u015bci<\/span><\/span> prze\u015blij<\/span><\/span> na adres<\/span><\/span>:<\/span><\/span><\/span> <\/em>
\nwebmaster@reunion68.com<\/a><\/span><\/span><\/strong><\/span><\/div>\n<\/div>\n<\/div>\n

 <\/p>\n

\n","protected":false},"excerpt":{"rendered":"

Possible hemophilia cure under study in Israeli hospital Brian Blum US biotech company BioMarin enlists aid of Sheba Medical Center to take part in international trials of a \u2018magic bullet\u2019 treatment for hemophilia A. Image by Jarun Ontakrai\/Shutterstock.com Is a cure for hemophilia on the horizon? American biotechnology company BioMarin aims to find out with […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[3],"tags":[26,24],"_links":{"self":[{"href":"https:\/\/www.reunion68.se\/index.php?rest_route=\/wp\/v2\/posts\/58987"}],"collection":[{"href":"https:\/\/www.reunion68.se\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.reunion68.se\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.reunion68.se\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.reunion68.se\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=58987"}],"version-history":[{"count":7,"href":"https:\/\/www.reunion68.se\/index.php?rest_route=\/wp\/v2\/posts\/58987\/revisions"}],"predecessor-version":[{"id":59170,"href":"https:\/\/www.reunion68.se\/index.php?rest_route=\/wp\/v2\/posts\/58987\/revisions\/59170"}],"wp:attachment":[{"href":"https:\/\/www.reunion68.se\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=58987"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.reunion68.se\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=58987"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.reunion68.se\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=58987"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}